<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342650</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 30504220.5.0000.0005</org_study_id>
    <nct_id>NCT04342650</nct_id>
  </id_info>
  <brief_title>Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection</brief_title>
  <acronym>CloroCOVID19II</acronym>
  <official_title>Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210
      individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who
      came to the study site with clinical and radiological suspicion of SARS-CoV2, will be
      randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets
      or placebo (tablet without active ingredient produced with the same physical
      characteristics).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with onset of severe acute respiratory syndrome (SARS)</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>after randomization, up to 28 days</time_frame>
    <description>Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants in need of intensive care support</measure>
    <time_frame>during and after intervention, up to 28 days</time_frame>
    <description>Proportion of participants in need and duration of intensive care support after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral concentration</measure>
    <time_frame>After randomization, up to 7 days</time_frame>
    <description>Viral load change in blood and oropharyngeal swab samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of serious adverse events</measure>
    <time_frame>During and after intervention, up to 28 days</time_frame>
    <description>Incidence of serious adverse events during and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade 3 and 4 adverse events</measure>
    <time_frame>During and after intervention, up to 28 days</time_frame>
    <description>Incidence of grade 3 and 4 adverse events during and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with discontinued treatment</measure>
    <time_frame>after randomization, up to 28 days</time_frame>
    <description>proportion of discontinuation or temporary suspension of treatment (for any reason)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiac lesions</measure>
    <time_frame>after randomization, up to 120 days</time_frame>
    <description>proportion of patients with increased levels of troponin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiac disfunctions</measure>
    <time_frame>after randomization, up to 120 days</time_frame>
    <description>proportion and magnitude of QTcF interval increases higher than 500ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory capacity</measure>
    <time_frame>Day 120 after randomization</time_frame>
    <description>Changes measured on day 120 will be compared to baseline, through spirometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <condition>Clinical Trial</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tables of equal characteristics and duration of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine Diphosphate</intervention_name>
    <description>150mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>chloroquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>150mg placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected cases of COVID-19, due to clinical and radiological data, during the
             epidemic;

          2. Adult aged 18 or over, at the time of inclusion

          3. Not having severe acute respiratory syndrome (SARS), that is, not using mechanical
             ventilation or supplemental oxygen, peripheral oxygen saturation&gt; 94% in room air, and
             having a respiratory rate below 24 incursions per minute.

          4. Patients with comorbidities only, due to the increased risk of developing SARS

        Exclusion Criteria:

        1. Patients with chronic use of drugs known to prolong QTc interval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69093-415</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all patient data will be shared after study publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after study publication</ipd_time_frame>
    <ipd_access_criteria>Upon formal request to researchers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

